The knockdown of FOXO3 led to sustained CSC self-renewal in glioblastoma, prostate, liver, and colorectal cancers and female cancers [185,186,187,188]; in contrast, leukemia-initiating cells require FOXO3 for stem cell survival [189,190]. Here, FOXO3 is linked to leukemia.